PharmD Signal

Deep dives, evidence grades, and clinical tools, all in one place.

Clinical Intelligence, Delivered

Evidence-based pharmacy analysis written by a PharmD, not a content farm.

PharmD Signal™ scans peer-reviewed literature daily and delivers structured deep-dive analyses designed for practicing clinical pharmacists and advanced pharmacy practitioners.

Start Reading Free →
🏅 Founding Member - Limited to 100

Lock in founding member pricing for life

Be one of the first 100 paid subscribers and keep your discounted rate as long as you stay subscribed. Once all spots are claimed, this pricing is gone.

4 of 100 spots claimed 96 remaining
$8 / mo
33% off regular $12/mo
Join Monthly →
BEST VALUE
$79 / yr
$6.58/mo - save 34% vs regular
Join Annually →
Secure checkout via Stripe. Cancel anytime from your Account page. Your founding rate stays locked as long as your subscription is active.
✉️ Sign Up Free

Get clinical evidence in your inbox

No credit card. No spam. Unsubscribe anytime. Free members get article alerts; upgrade anytime for full deep analyses.

Already have an account? Log in

📨 Newsletter Only

Just want the email digest?

Get article alerts in your inbox without creating an account. You can upgrade anytime.

🔓 Try It First: Free Samples

Read two complete deep analyses before you commit to anything. No account needed.

Confirmatory Nephrology / Renal Pharmacy
Finerenone Outperforms Spironolactone for Cardiorenal Protection in Moderate CKD
Jul 20, 2026 · American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions

Finerenone emerges as the safer choice for CKD patients.

Read Full Deep Analysis (Free) →
Confirmatory Neurology / Neuropharmacology
Tenecteplase Shortens Stroke Treatment and Transfer Times
Jul 13, 2026 · JAMA Network Open

Tenecteplase speeds up stroke thrombolysis compared to alteplase.

Read Full Deep Analysis (Free) →

Free vs. Premium

Free
$0 / month
  • ✓  New article alerts, daily
  • ✓  Headline & clinical hook
  • ✓  High-level summary (why it matters, key results, takeaway)
  • ✓  PubMed source link
  • ✓  Verdict tag (Practice-changing, Confirmatory…)
  • ✓  GRADE evidence quality rating
  • —  Full deep analysis
  • —  Pharmacist implications
  • —  Downloadable PDF report
Sign Up Free →
Premium
$12 / month
or $120/year (save ~17%)
  • ✓  Everything in Free
  • ✓  Full deep analysis: study design, population, endpoints, safety
  • ✓  Structured pharmacist implications
  • ✓  Clinical pearls & guideline context
  • ✓  Controversies & evidence gaps
  • ✓  Downloadable PDF report
  • ✓  Topic preferences (Cardiology, ID, Oncology…)
  • ✓  Full archive access
  • ✓  PharmD Clinical Reference (coming)
Subscribe Monthly, $12/mo → Subscribe Annually, $120/yr →
Secure checkout via Stripe. Cancel anytime from your Account page.

What a Deep Analysis Looks Like

Every paid deep analysis is a structured clinical breakdown, not a bullet-point summary. Here's what's inside each one:

📝
Executive Summary
The 3-sentence verdict. What the study found, whether it matters, what you do Monday morning.
🔬
Study Design
Trial type, blinding, randomization, follow-up period, and key design decisions that affect interpretation.
👥
Patient Population
Who was enrolled, key inclusion/exclusion criteria, and how generalizable the findings are to your patients.
🎯
Primary Outcomes
Results tables with effect sizes, CIs, and p-values, formatted the way you'd present at journal club.
⚠️
Safety Profile
Adverse events, discontinuation rates, and signals that matter clinically, not just what reached significance.
🎓
Pharmacist Implications
Numbered, specific, practice-focused, written by a PharmD for pharmacists, not for a general audience.
💡
Clinical Pearls
High-yield takeaways for the bedside or the phone.
📊
GRADE Evidence Rating
High / Moderate / Low / Very Low with rationale, so you know how much weight to put on this trial.
📄
Downloadable PDF
Full report formatted for printing, sharing at rounds, or keeping in your reference folder.

Why PharmD Signal™?

🎓
PharmD-curated
Every analysis approved by a licensed pharmacist. Not AI alone, not generic health content.
🔬
Structured for clinicians
Study design, endpoints, safety, pharmacist implications, GRADE evidence quality, the way you were trained to read literature.
📅
Reviewed daily
New literature is reviewed every morning for clinical impact, study robustness, and accuracy. High-impact studies are triaged and analyzed the same day.
⚡
Built for busy clinicians
Verdict tags, evidence grades, and clinical pearls let you skim fast or dig deep, on your schedule.

Coverage Areas

High-impact clinical pharmacy domains, reviewed by a PharmD before anything reaches subscribers.

CardiologyAnticoagulation / HematologyInfectious Disease / AntimicrobialsOncologyAmbulatory Care / MTMMedication SafetyPharmacokinetics / TDMClinical PracticeCritical Care / ICUPediatricsEndocrinology / Diabetes / ObesityNeurology / NeuropharmacologyGeriatricsPain ManagementPalliative CareGastroenterology / HepatologyNephrologyBehavioral Health / Addiction MedicinePulmonology / RespiratoryRheumatology / ImmunologyPsychiatry / PsychopharmacologyWomen's Health / ReproductivePerioperative / AnesthesiaEmergency Medicine / Toxicology

New categories are added regularly as coverage expands.

🎓
On the roadmap

CE credit is coming

We're working toward ACPE-accredited continuing education tied to our deep analyses, earn CE while you stay current. Free subscribers will be the first to know when it launches.

Join Free. Get Notified →

Frequently Asked Questions

Is every article actually reviewed by a PharmD?
Yes. Every article that reaches subscribers has been manually reviewed and approved by a licensed pharmacist. AI generates the structured draft; the PharmD verifies clinical accuracy, selects the verdict, assigns the GRADE evidence rating, and decides what actually gets published. Articles that don't meet the bar are declined. They never reach your inbox.
How often do new analyses come out?
New articles are reviewed every day for inclusion based on clinical impact, study robustness, and accuracy. The number of published analyses varies by week depending on what's actually worth your time. Expect several per week during active publishing periods. Quality over volume.
What topics are covered?
Cardiology/anticoagulation, infectious disease/antimicrobials, oncology pharmacy, ambulatory care/MTM, medication safety, pharmacokinetics/TDM, clinical pharmacy practice, critical care/ICU, pediatric pharmacy, and more. New specialty areas are added regularly as coverage expands. Topic preferences let paid subscribers filter to only what's relevant to their practice.
How is this different from a journal alert or PubMed RSS feed?
A journal alert gives you a title and abstract. PharmD Signal gives you a structured clinical breakdown with study design, results tables, safety data, GRADE evidence rating, and pharmacist-specific implications, reviewed by a clinician, not just indexed by an algorithm. It's the difference between raw data and a usable clinical tool.
How do I cancel or manage my paid subscription?
Log in and go to your Account page. The Manage Subscription & Billing link takes you to a secure self-service portal where you can update your card, view invoices, or cancel anytime. Cancelling stops future renewals; you keep access through the end of your current paid period.
No credit card. No spam. Just clinical evidence.

Ready to stay current?

Join clinical pharmacists who read PharmD Signal to keep up with the evidence.

Sign Up Free →
Takes 30 seconds · Unsubscribe anytime

← Back to Home